Skip to main content

Table 1 Melanoma cell line sensitivity to PI3K/Akt and mTOR pathway inhibition

From: Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

Compound Target IC50±SEM
B16.F10 A375 RPMI SH4 MeWo MEL-JUSO
MK-2206 Pan-AKT 0.29±0.05 4.76±0.58 1.92±0.36 3.11±0.91 1.26±0.01 3.03±0.35
ZSTK474 PI3K 0.95±0.33 2.69±1.14 0.51±0.05 2.80±0.81 1.06±0.07 3.47±0.28
KU-0063794 Pan-mTOR 0.68±0.26 1.90±1.45 1.63±0.28 1.71±0.86 0.97±0.05 1.84±0.12